Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of repinatrabit (JNT-517) in phenylketonuria
NL-OMON58872Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of repinatrabit in phenylketonuria (PKU) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Absolute change in plasma phenylalanine. Started Jan 2026; status: recruiting.
02
Drugs
repinatrabit
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NL-OMON58872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58872.